Population pharmacokinetic of paracetamol and atorvastatin with co‐administration of semaglutide
Abstract Semaglutide is a glucagon‐like‐peptide‐1 (GLP‐1) analogue marketed for once‐weekly subcutaneous administration for type 2 diabetes mellitus. Like other long‐acting GLP‐1 analogues, semaglutide reduces gastric emptying and, potentially, alters the rate of absorption of orally co‐administered...
Saved in:
Main Authors: | Emilie K. Langeskov (Author), Kim Kristensen (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
by: Sejung Hwang, et al.
Published: (2021) -
Clinical Pharmacokinetics of Semaglutide: A Systematic Review
by: Yang XD, et al.
Published: (2024) -
Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration
by: Evgenia Koureta, et al.
Published: (2024) -
Semaglutide for the treatment of obesity
by: Rafał Oleszczuk, et al.
Published: (2022) -
Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets
by: Ghim JL, et al.
Published: (2019)